USANA Health Sciences (USNA) to Release Quarterly Earnings on Tuesday

USANA Health Sciences (NYSE:USNA) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, October 22nd. Analysts expect the company to announce earnings of $0.49 per share for the quarter. USANA Health Sciences has set its FY 2024 guidance at 2.400-2.550 EPS.Investors interested in registering for the company’s conference call can do so using this link.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, July 23rd. The company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.11). USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. The firm had revenue of $212.87 million for the quarter, compared to analyst estimates of $218.64 million. During the same quarter in the prior year, the firm earned $0.89 earnings per share. On average, analysts expect USANA Health Sciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

USANA Health Sciences Price Performance

NYSE USNA opened at $35.85 on Friday. USANA Health Sciences has a fifty-two week low of $34.76 and a fifty-two week high of $57.78. The business has a fifty day moving average price of $38.15 and a two-hundred day moving average price of $42.79. The stock has a market capitalization of $682.98 million, a PE ratio of 11.17, a PEG ratio of 1.19 and a beta of 0.89.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on USNA. StockNews.com lowered USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 24th. DA Davidson reduced their price target on shares of USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating on the stock in a research note on Thursday, July 25th.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, Director John Turman Fleming sold 1,000 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total value of $44,430.00. Following the completion of the transaction, the director now directly owns 2,503 shares in the company, valued at approximately $111,208.29. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other USANA Health Sciences news, Director John Turman Fleming sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total transaction of $44,430.00. Following the sale, the director now directly owns 2,503 shares of the company’s stock, valued at $111,208.29. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gilbert A. Fuller sold 674 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total transaction of $26,751.06. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,940 shares of company stock worth $311,670. Corporate insiders own 0.33% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.